Contraceptive applications of progesterone receptor modulators

Nathalie Chabbert-Buffet, Nathalie Chabbert‐Buffet, Chabbert-Buffet N, Sophie Ouzounian, Ouzounian S, Axelle Pintiaux Kairis, Kairis AP, Bouchard P, Philippe Bouchard
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2008 · vol. 13(3) , pp. 222–230 · doi:10.1080/13625180802267060 · PMID:18821461 · W2020170934
Review OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

Progesterone receptor modulators demonstrate contraceptive potential through mechanisms like ovulation blockade and endometrial desynchronization, with future applications in emergency contraception, estrogen-free options, endometriosis, and myoma treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Currently developed progesterone receptor modulators (PRMs) are steroid-derived compounds with mild or potent antiprogestin activity. PRMs may exert a contraceptive activity by different mechanisms such as blockade of ovulation and endometrial desynchronization. Their potential clinical applications are manifold and are very promising in major public health areas, including emergency contraception, long term oestrogen-free contraception (administered alone, or in association with a progestin-only pill to improve bleeding patterns), endometriosis and myoma treatment. The mechanisms of their anti-ovulatory effects and of the endometrial modifications elicited during long term PRM treatment are still not fully elucidated. In future clinical applications, PRMs will be administered orally, via intrauterine systems or vaginal rings.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Contraceptives, Oral, Hormonal Contraceptives, Postcoital Receptors, Progesterone Contraceptive Agents, Female Contraceptive Agents, Female Contraceptive Agents, Female Contraceptives, Oral, Hormonal Contraceptives, Oral, Hormonal Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Contraceptives, Postcoital Contraceptives, Postcoital Female Female Humans Humans Mifepristone Mifepristone Mifepristone

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (54)

Cited by (1)

Source provenance

europepmc
last seen: 2026-10-18T09:30:06.152893+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:05:43.569505+00:00
unpaywall
last seen: 2026-10-18T06:28:46.490043+00:00
License: CC0 · commercial use OK